Friday Dec 18 | Newkerala.com
Chemo drugs may lead to cognitive decline
Washington, Dec 18 : A new study from University of Rochester Medical Centre has shown that four commonly used chemotherapy drugs disrupt the birth of new brain cells, eventually leading to a decline in cognitive function.
PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer
E-mail: zsalab2@yahoo.com Received 4 August 2009; Revised 6 November 2009; Accepted 11 November 2009; Published online 15 December 2009.
Supplementary vitamin C might hinder cancer chemotherapy
Vitamin C supplements taken during chemotherapy might substantially reduce the benefits of that therapy, according to a recent group of in vitro and animal studies of cancer cells.
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and...
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102 Export J Clin Oncol , Vol.
Expulsion of amplified MYCN from homogenously staining chromosomal...
Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine.
Inability of Pixantrone to Form Toxic Iron Complexes Results in...
Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al.
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Oxidative stress, directly or indirectly caused by chemotherapeutics as exemplified by doxorubicin, is one of the underlying mechanisms of the toxicity of anticancer drugs in noncancerous tissues, including the heart and brain.
Single-walled carbon nanotube-conjugated chemotherapy exhibits...
HST Center for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Science and Technology, Cambridge, MA 02139, USA 1 Address for correspondence: 65 Landsdowne Street, Partners Research Building, Room # 325, Cambridge, MA 02139, USA E-mail: shiladit@mit.edu Abstract.
Cyclooxygenase-2 inhibitors prevent the development of...
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
In this study, we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human breast cancer cells.
Population-Based Analysis of the Frequency of Anemia and its...
OBJECTIVE:: In patients with hematologic malignancies, chemotherapy can further suppress bone marrow production.
Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage
This release is available in French and Spanish . IMAGE: This image shows the effect of gene therapy combined with cytotoxic agents in E spheroids derived from breast cancer cell line MCF-7. A. Control; B. Doxorubicin 10nm, C. Paclitaxel 10nm,... Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the ...
CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer
CytRx Corporation , a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric cancer.
Doxorubicin Loaded Polymeric Nanoparticulate Delivery System to...
Drug resistance is a primary hindrance for the efficiency of chemotherapy against osteosarcoma.
Self-assembling chimeric polypeptidea "doxorubicin conjugate...
Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection Abstract New strategies to self-assemble biocompatible materials into nanoscale, drug-loaded packages with improved therapeutic efficacy are needed for nanomedicine.
Ziopharm Sarcoma Trial Gets Promising Data
Ziopharm Oncology, Inc. achieved positive data from the multicenter randomized Phase II trial of palifosfamide in patients with unresectable or metastatic soft tissue sarcoma.
Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2...
Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009.
Two-In-One Punch Knocks Out Drug Resistant Cancer Cells
Cancer cells, like bacteria, can develop resistance to drug therapy, leading to relapse of disease.
Early detection of patients with poor risk diffuse large B-cell lymphoma.
More than 60% of patients with diffuse large B-cell lymphoma will be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone .
Duke develops nano-scale drug delivery for chemotherapy
Going smaller could bring better results, especially when it comes to cancer-fighting drugs.
Also on Topix